The global GLP-1 receptor agonists market was valued at USD 78.4 billion in 2025. It is estimated at USD 88.6 billion in 2026 and is projected to reach USD 200.3 billion by 2036, growing at a CAGR of 8.5% over the 2026-2036 forecast period. This report assesses the market in depth, covering epidemiology, the pipeline, outcomes evidence, patent expiry, regulation and safety, pricing and reimbursement, manufacturing, and competition.
The study covers medicines that activate the glucagon-like peptide-1 receptor to control blood sugar, curb appetite, and support weight loss, along with multi-receptor drugs that add GIP, glucagon, or amylin activity. It includes marketed mono-agonists such as semaglutide (Ozempic, Wegovy, and Rybelsus), liraglutide, dulaglutide, and exenatide, the dual GIP/GLP-1 agonist tirzepatide (Mounjaro and Zepbound), oral peptides and small-molecule agonists, late-stage next-generation candidates, and generic and biosimilar versions as patents lapse. Indications span diabetes, weight management, and heart, kidney, sleep apnea, and liver disease.
GLP-1 drugs now form the largest therapy class in the pharmaceutical industry, and Eli Lilly reported 2025 sales of USD 22.97 billion for Mounjaro and USD 13.54 billion for Zepbound, which made tirzepatide the best-selling medicine in the world, while Novo Nordisk reported obesity care sales of DKK 82.3 billion in 2025, up from DKK 65.1 billion a year earlier. The underlying patient pool is very large: according to the World Health Organization, one in eight people worldwide was living with obesity in 2022, and some 2.5 billion adults were overweight. In December 2025, the WHO released its first guideline conditionally recommending GLP-1 therapies for adults with obesity.
Lower prices are the main restraint on value growth, and Lilly reported that in the last quarter of 2025 its volume grew 46% while realized prices fell 5%, partly because of its agreement with Washington. Novo Nordisk reported that it will cut American list prices of Wegovy and Ozempic to USD 675 from January 2027, and Medicare access at a lower negotiated price begins in mid-2026. Semaglutide's compound patent expires in 2026 in several international markets, including Canada, China, Brazil, and India, and liraglutide is already off-patent. Persistence is weak, as a 2025 study in JAMA Network Open reported that nearly half of patients with type 2 diabetes and about two-thirds of those without diabetes discontinued within one year. Safety signals add caution, after European regulators concluded in mid-2025 that semaglutide can, very rarely, cause NAION, an eye condition that may lead to vision loss. Other challenges include compounded and counterfeit supply, limited obesity coverage, manufacturing capacity, and pipeline risk.
Opportunities include generic and lower-cost GLP-1s for emerging markets, manufacturer direct-to-consumer and cash-pay channels such as LillyDirect and NovoCare, and multi-agonist combinations that promise greater weight loss. Key trends include the move to oral therapy, volume growth paired with falling net prices, higher doses and multi-receptor agonists such as Wegovy 7.2 mg, CagriSema, and retatrutide, and rising deal activity. Notable deals include Roche's 2025 partnership with Zealand Pharma on petrelintide and Pfizer's November 2025 acquisition of Metsera after a bidding contest with Novo Nordisk.
Based on molecule, the report covers semaglutide (Ozempic, Wegovy injection and pill, and Rybelsus), tirzepatide (Mounjaro and Zepbound), liraglutide, dulaglutide, exenatide & others, and next-generation agonists. Tirzepatide is expected to hold the largest share in 2026. Its dual GIP and GLP-1 action delivers greater weight loss than earlier agents, Mounjaro and Zepbound are being rolled out quickly across diabetes and obesity in many countries, and Zepbound is also sold at lower cash prices through LillyDirect. Next-generation agonists are expected to grow at the highest CAGR during the forecast period, as oral small molecules such as orforglipron, amylin combinations such as CagriSema, and triple agonists such as retatrutide reach the market.
By mechanism, the market is divided into mono GLP-1 agonists, dual agonists (GIP/GLP-1, GLP-1/glucagon, and GLP-1/amylin combinations), and triple agonists. Mono GLP-1 agonists are expected to hold the largest share in 2026, reflecting the large patient base already treated with semaglutide, liraglutide, and dulaglutide for diabetes and obesity and the arrival of cheaper generic versions outside the U.S. and Europe. Triple agonists are expected to grow at the highest CAGR, as candidates such as retatrutide aim for weight loss closer to bariatric surgery and are expected to launch in the second half of the forecast period.
The route of administration analysis covers injectable (once-weekly and once-daily) and oral (oral peptides and oral small molecules) products. Injectables are expected to account for the larger share in 2026, since the leading brands, Mounjaro, Zepbound, Ozempic, and Wegovy, are once-weekly injections used in both diabetes and obesity. Oral products are expected to grow at the higher CAGR, supported by the January 2026 launch of the Wegovy pill, which reached about 50,000 weekly prescriptions within three weeks, the likely approval of orforglipron, and the wish of many patients to avoid injections.
Indications studied include type 2 diabetes, obesity & overweight, cardiovascular risk reduction, CKD, sleep apnea, MASH, and others. Type 2 diabetes is expected to hold the largest share in 2026, owing to well-established treatment guidelines, broad insurance coverage, and the large number of patients already on Mounjaro, Ozempic, Trulicity, and Rybelsus. Obesity & overweight is expected to grow at the highest CAGR, driven by rising prevalence, the WHO's December 2025 guideline, wider Medicare access from mid-2026, and the availability of oral options.
Between the two product types, branded and generic, branded products are expected to hold the larger share in 2026, as tirzepatide remains under patent worldwide and semaglutide stays protected in the U.S. and Europe. Generic products are expected to grow at the higher CAGR, as semaglutide loses compound patent protection in several international markets from 2026 and generic liraglutide is already available worldwide.
By distribution channel, the report covers retail pharmacies, hospital pharmacies, and online & direct-to-consumer. Retail pharmacies are expected to account for the largest share in 2026, as GLP-1 drugs are long-term outpatient treatments and most insured prescriptions are filled through retail networks. Online & direct-to-consumer channels are expected to grow at the highest CAGR, helped by company-run platforms, telehealth prescribing, and strong cash-pay uptake of the Wegovy pill.
By payer channel, which covers commercial insurance, public payers, and self-pay, commercial insurance is expected to hold the largest share in 2026, as employers and health plans cover GLP-1s for type 2 diabetes and, increasingly, for obesity. Self-pay is expected to grow at the highest CAGR, as cash prices fall sharply and many insurers still exclude obesity treatment. Public payers are set to gain importance as Medicare obesity coverage begins under the 2025 agreements.
North America is expected to be the largest regional market in 2026, supported by high rates of obesity and diabetes, strong commercial insurance, and early access to new drugs. The U.S. is the main market for Zepbound and the first market for the Wegovy pill, and the November 2025 agreements will open Medicare access from mid-2026. In Canada, semaglutide lost compound patent protection in 2026. Europe holds a significant share and is home to Novo Nordisk, but reimbursement differs widely, as the U.K.'s National Health Service started offering Mounjaro through general practitioners in June 2025, while German statutory insurance does not pay for weight-loss drugs.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by its large diabetic population, rising obesity, wider reimbursement, and the entry of low-cost generics and local innovators. In China, the Supreme People's Court confirmed the semaglutide patent in December 2025, shortly before it lapses in 2026, a liraglutide biosimilar was approved in 2023, and Innovent's dual agonist mazdutide was approved in 2025. Low-priced generics should follow in India once semaglutide protection ends in 2026, while Japan launched Wegovy for obesity in 2024. In Latin America, Brazil faces generic semaglutide competition from 2026 and Mexico, Argentina, Colombia, and Chile have large cash-pay markets. The Middle East & Africa is expected to post strong growth from a smaller base, as Saudi Arabia, the UAE, Kuwait, and Qatar have some of the world's highest obesity and diabetes rates; according to the International Diabetes Federation, some 73 million adults across the Middle East and North Africa were diabetic in 2021.
The market is highly concentrated, as Eli Lilly and Novo Nordisk together generate most class revenue. Behind them are large pharmaceutical and biotech challengers, fast-growing Chinese developers, and generic makers preparing for semaglutide's loss of exclusivity. Main strategies include launching oral products, pursuing higher doses and multi-agonist combinations, adding fill-finish capacity, as with Novo Holdings' purchase of Catalent in December 2024, cutting prices, building direct channels, and licensing or acquiring next-generation assets.
Key companies profiled in the report include Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca PLC (U.K.), Boehringer Ingelheim International GmbH (Germany), Zealand Pharma A/S (Denmark), Viking Therapeutics, Inc. (U.S.), Structure Therapeutics Inc. (U.S.), Innovent Biologics, Inc. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), Hangzhou Jiuyuan Gene Engineering Co., Ltd. (China), Huadong Medicine Co., Ltd. (China), Hanmi Pharmaceutical Co., Ltd. (South Korea), Dr. Reddy's Laboratories Ltd. (India), Biocon Limited (India), Sun Pharmaceutical Industries Ltd. (India), Sandoz Group AG (Switzerland), and Teva Pharmaceutical Industries Ltd. (Israel).
The study covers medicines that activate the glucagon-like peptide-1 receptor to control blood sugar, curb appetite, and support weight loss, along with multi-receptor drugs that add GIP, glucagon, or amylin activity. It includes marketed mono-agonists such as semaglutide (Ozempic, Wegovy, and Rybelsus), liraglutide, dulaglutide, and exenatide, the dual GIP/GLP-1 agonist tirzepatide (Mounjaro and Zepbound), oral peptides and small-molecule agonists, late-stage next-generation candidates, and generic and biosimilar versions as patents lapse. Indications span diabetes, weight management, and heart, kidney, sleep apnea, and liver disease.
GLP-1 drugs now form the largest therapy class in the pharmaceutical industry, and Eli Lilly reported 2025 sales of USD 22.97 billion for Mounjaro and USD 13.54 billion for Zepbound, which made tirzepatide the best-selling medicine in the world, while Novo Nordisk reported obesity care sales of DKK 82.3 billion in 2025, up from DKK 65.1 billion a year earlier. The underlying patient pool is very large: according to the World Health Organization, one in eight people worldwide was living with obesity in 2022, and some 2.5 billion adults were overweight. In December 2025, the WHO released its first guideline conditionally recommending GLP-1 therapies for adults with obesity.
Market Dynamics
Demand is driven by rising obesity and type 2 diabetes, new approved uses, and new formats. Labels have widened steadily: the FDA cleared Wegovy for cardiovascular risk reduction in March 2024 after the SELECT trial, Zepbound for obstructive sleep apnea in December 2024, Ozempic for kidney disease in January 2025, and Wegovy for MASH with liver fibrosis in August 2025. Oral therapy is the latest step, with the Wegovy pill cleared by the FDA on 22 December 2025, and Lilly has filed its small-molecule agonist orforglipron in the U.S., Japan, and the EU.Lower prices are the main restraint on value growth, and Lilly reported that in the last quarter of 2025 its volume grew 46% while realized prices fell 5%, partly because of its agreement with Washington. Novo Nordisk reported that it will cut American list prices of Wegovy and Ozempic to USD 675 from January 2027, and Medicare access at a lower negotiated price begins in mid-2026. Semaglutide's compound patent expires in 2026 in several international markets, including Canada, China, Brazil, and India, and liraglutide is already off-patent. Persistence is weak, as a 2025 study in JAMA Network Open reported that nearly half of patients with type 2 diabetes and about two-thirds of those without diabetes discontinued within one year. Safety signals add caution, after European regulators concluded in mid-2025 that semaglutide can, very rarely, cause NAION, an eye condition that may lead to vision loss. Other challenges include compounded and counterfeit supply, limited obesity coverage, manufacturing capacity, and pipeline risk.
Opportunities include generic and lower-cost GLP-1s for emerging markets, manufacturer direct-to-consumer and cash-pay channels such as LillyDirect and NovoCare, and multi-agonist combinations that promise greater weight loss. Key trends include the move to oral therapy, volume growth paired with falling net prices, higher doses and multi-receptor agonists such as Wegovy 7.2 mg, CagriSema, and retatrutide, and rising deal activity. Notable deals include Roche's 2025 partnership with Zealand Pharma on petrelintide and Pfizer's November 2025 acquisition of Metsera after a bidding contest with Novo Nordisk.
Segment Analysis
The report analyzes the market by molecule, mechanism, route of administration, indication, product type, distribution channel, payer channel, and geography, helping stakeholders see where demand and value are moving.Based on molecule, the report covers semaglutide (Ozempic, Wegovy injection and pill, and Rybelsus), tirzepatide (Mounjaro and Zepbound), liraglutide, dulaglutide, exenatide & others, and next-generation agonists. Tirzepatide is expected to hold the largest share in 2026. Its dual GIP and GLP-1 action delivers greater weight loss than earlier agents, Mounjaro and Zepbound are being rolled out quickly across diabetes and obesity in many countries, and Zepbound is also sold at lower cash prices through LillyDirect. Next-generation agonists are expected to grow at the highest CAGR during the forecast period, as oral small molecules such as orforglipron, amylin combinations such as CagriSema, and triple agonists such as retatrutide reach the market.
By mechanism, the market is divided into mono GLP-1 agonists, dual agonists (GIP/GLP-1, GLP-1/glucagon, and GLP-1/amylin combinations), and triple agonists. Mono GLP-1 agonists are expected to hold the largest share in 2026, reflecting the large patient base already treated with semaglutide, liraglutide, and dulaglutide for diabetes and obesity and the arrival of cheaper generic versions outside the U.S. and Europe. Triple agonists are expected to grow at the highest CAGR, as candidates such as retatrutide aim for weight loss closer to bariatric surgery and are expected to launch in the second half of the forecast period.
The route of administration analysis covers injectable (once-weekly and once-daily) and oral (oral peptides and oral small molecules) products. Injectables are expected to account for the larger share in 2026, since the leading brands, Mounjaro, Zepbound, Ozempic, and Wegovy, are once-weekly injections used in both diabetes and obesity. Oral products are expected to grow at the higher CAGR, supported by the January 2026 launch of the Wegovy pill, which reached about 50,000 weekly prescriptions within three weeks, the likely approval of orforglipron, and the wish of many patients to avoid injections.
Indications studied include type 2 diabetes, obesity & overweight, cardiovascular risk reduction, CKD, sleep apnea, MASH, and others. Type 2 diabetes is expected to hold the largest share in 2026, owing to well-established treatment guidelines, broad insurance coverage, and the large number of patients already on Mounjaro, Ozempic, Trulicity, and Rybelsus. Obesity & overweight is expected to grow at the highest CAGR, driven by rising prevalence, the WHO's December 2025 guideline, wider Medicare access from mid-2026, and the availability of oral options.
Between the two product types, branded and generic, branded products are expected to hold the larger share in 2026, as tirzepatide remains under patent worldwide and semaglutide stays protected in the U.S. and Europe. Generic products are expected to grow at the higher CAGR, as semaglutide loses compound patent protection in several international markets from 2026 and generic liraglutide is already available worldwide.
By distribution channel, the report covers retail pharmacies, hospital pharmacies, and online & direct-to-consumer. Retail pharmacies are expected to account for the largest share in 2026, as GLP-1 drugs are long-term outpatient treatments and most insured prescriptions are filled through retail networks. Online & direct-to-consumer channels are expected to grow at the highest CAGR, helped by company-run platforms, telehealth prescribing, and strong cash-pay uptake of the Wegovy pill.
By payer channel, which covers commercial insurance, public payers, and self-pay, commercial insurance is expected to hold the largest share in 2026, as employers and health plans cover GLP-1s for type 2 diabetes and, increasingly, for obesity. Self-pay is expected to grow at the highest CAGR, as cash prices fall sharply and many insurers still exclude obesity treatment. Public payers are set to gain importance as Medicare obesity coverage begins under the 2025 agreements.
Regional Analysis
The study spans five regions, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 22 countries, Kuwait & Qatar, Denmark & the Nordic countries, and five rest-of-region groups. It considers disease prevalence, reimbursement, patent status, and pricing.North America is expected to be the largest regional market in 2026, supported by high rates of obesity and diabetes, strong commercial insurance, and early access to new drugs. The U.S. is the main market for Zepbound and the first market for the Wegovy pill, and the November 2025 agreements will open Medicare access from mid-2026. In Canada, semaglutide lost compound patent protection in 2026. Europe holds a significant share and is home to Novo Nordisk, but reimbursement differs widely, as the U.K.'s National Health Service started offering Mounjaro through general practitioners in June 2025, while German statutory insurance does not pay for weight-loss drugs.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by its large diabetic population, rising obesity, wider reimbursement, and the entry of low-cost generics and local innovators. In China, the Supreme People's Court confirmed the semaglutide patent in December 2025, shortly before it lapses in 2026, a liraglutide biosimilar was approved in 2023, and Innovent's dual agonist mazdutide was approved in 2025. Low-priced generics should follow in India once semaglutide protection ends in 2026, while Japan launched Wegovy for obesity in 2024. In Latin America, Brazil faces generic semaglutide competition from 2026 and Mexico, Argentina, Colombia, and Chile have large cash-pay markets. The Middle East & Africa is expected to post strong growth from a smaller base, as Saudi Arabia, the UAE, Kuwait, and Qatar have some of the world's highest obesity and diabetes rates; according to the International Diabetes Federation, some 73 million adults across the Middle East and North Africa were diabetic in 2021.
Competitive Landscape
The report includes a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with industry leaders, market differentiators, vanguards, and emerging companies, and 2025 market share/rank analysis. Company profiles of market leaders, pipeline challengers, Asia-Pacific developers, and generic manufacturers cover business overview, financial overview, product portfolio, pipeline, strategic developments, and SWOT analysis.The market is highly concentrated, as Eli Lilly and Novo Nordisk together generate most class revenue. Behind them are large pharmaceutical and biotech challengers, fast-growing Chinese developers, and generic makers preparing for semaglutide's loss of exclusivity. Main strategies include launching oral products, pursuing higher doses and multi-agonist combinations, adding fill-finish capacity, as with Novo Holdings' purchase of Catalent in December 2024, cutting prices, building direct channels, and licensing or acquiring next-generation assets.
Key companies profiled in the report include Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca PLC (U.K.), Boehringer Ingelheim International GmbH (Germany), Zealand Pharma A/S (Denmark), Viking Therapeutics, Inc. (U.S.), Structure Therapeutics Inc. (U.S.), Innovent Biologics, Inc. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), Hangzhou Jiuyuan Gene Engineering Co., Ltd. (China), Huadong Medicine Co., Ltd. (China), Hanmi Pharmaceutical Co., Ltd. (South Korea), Dr. Reddy's Laboratories Ltd. (India), Biocon Limited (India), Sun Pharmaceutical Industries Ltd. (India), Sandoz Group AG (Switzerland), and Teva Pharmaceutical Industries Ltd. (Israel).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global GLP-1 receptor agonists market through 2036.
- Explains how obesity and diabetes prevalence, label expansion, and oral and next-generation agonists are shaping demand.
- Assesses the impact of U.S. price agreements, list price cuts, semaglutide patent expiry, poor persistence, and safety signals on market value.
- Tracks the pipeline of oral small molecules, dual and triple agonists, amylin combinations, and muscle-preserving therapies.
- Identifies high-growth opportunities across molecule, mechanism, route, indication, product type, distribution channel, payer channel, and region.
- Benchmarks originators, pipeline challengers, Asian developers, and generic makers on portfolios, pipelines, and deals.
- Supports portfolio planning, business development, pricing and market access, manufacturing investment, and market entry decisions for drug makers, investors, payers, and pharmacies.
Key Questions Answered
- How large is the global GLP-1 receptor agonists market today, and how will it grow through 2036?
- How will falling net prices and rising treatment volumes change the economics of the class?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will semaglutide's loss of exclusivity in international markets affect originators and generic makers?
- How quickly will oral GLP-1s, triple agonists, and amylin combinations gain adoption?
- Which molecule, mechanism, route, indication, distribution channel, and payer channel segments will grow the fastest?
- Which regions and countries offer the most attractive opportunities?
- Who are the leading companies in the market, and how do they compare?
- What approvals, licensing deals, acquisitions, and capacity investments are shaping competition?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. GLP-1 Receptor Agonists Market, by Molecule
6. GLP-1 Receptor Agonists Market, by Mechanism
7. GLP-1 Receptor Agonists Market, by Route of Administration
8. GLP-1 Receptor Agonists Market, by Indication
9. GLP-1 Receptor Agonists Market, by Product Type
10. GLP-1 Receptor Agonists Market, by Distribution Channel
11. GLP-1 Receptor Agonists Market, by Payer Channel
12. GLP-1 Receptor Agonists Market, by Geography
13. Competitive Landscape
14. Company Profiles
15. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Novo Nordisk A/S
- Eli Lilly and Company
- Amgen Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Zealand Pharma A/S
- Viking Therapeutics, Inc.
- Structure Therapeutics Inc.
- Innovent Biologics, Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Hangzhou Jiuyuan Gene Engineering Co., Ltd.
- Huadong Medicine Co., Ltd.
- Hanmi Pharmaceutical Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Biocon Limited
- Sun Pharmaceutical Industries Ltd.
- Sandoz Group AG
- Teva Pharmaceutical Industries Ltd.
